Table 5. Treatment regimens for sofosbuvir combination therapy1.
| Monoinfected HCV or HCV/HIV-1 coinfections | Treatment regimen | Duration |
| Genotype 1 or 4 chronic hepatitis C | Sofosbuvir with peginterferon alfaa and ribavirina,b | 12 weeksc |
| Genotype 2 chronic hepatitis C | Sofosbuvir and ribavirina,b | 12 weeks |
| Genotype 3 chronic hepatitis C | Sofosbuvir and ribavirina,b | 24 weeks |
| Hepatocellular carcinoma awaiting liver transplant | Sofosbuvir and ribavirina,b | 48 weeks or up to time of liver transplant |
a
For complete information, refer to the prescribing information of each respective agent.
b
Based on weight; patients weighing < 5 kg should receive 1,000 mg and patients weighing ≥75 kg should receive 1,200 mg. Both regimens are to be taken with food and in 2 divided doses. The dose should be reduced in patients with creatinine clearance ≤50 mL/min.
c
After consideration of risks versus benefits, patients who are interferon ineligible may consider treatment with sofosbuvir plus ribavirin for 24 weeks.